Protagen to ID Protein Biomarkers in Support of Biogen's MS Drug Development Work
April 01, 2011
Protagen to ID Protein Biomarkers in Support of Biogen's MS Drug Development Work
The company will use its UNIarray protein array platform to retrospectively analyze samples from a clinical trial in hopes of finding predictive and response biomarkers for relapsing/remitting multiple sclerosis.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Protagen Secures Nearly $13M in Funding for Diagnostics Work and Protein Biomarker Validation
September 10, 2010 / ProteoMonitor - Protagen Using UNIarray Platform to ID Biomarkers for Use in Lupus Drug Development
August 5, 2011 / ProteoMonitor - Protagen Collaborates with Bayer Schering on Endometriosis Biomarker Discovery
June 11, 2010 / ProteoMonitor - SuppreMol to Use Protagen Biomarker Panel
August 2, 2011 / GenomeWeb Daily News - Protagen Receives Japanese Patent for UNIclone Technology
August 13, 2010 / ProteoMonitor